ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.
ImmuCell (NASDAQ:ICCC - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter. ImmuCell had a return on equity of 6.25...
MarketBeat·27d ago
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average - Time to Sell?
ImmuCell (NASDAQ:ICCC) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?
ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average - What's Next...
MarketBeat·29d ago
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
Zacks·2mo ago
Top Stock Reports for SAP, Novartis & Philip Morris
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
Zacks·2mo ago
FONAR's Stock Advances 5% in Three Months: Key Trends Ahead
FONR leverages hybrid MRI tech and a strong balance sheet to navigate industry headwinds, though rising costs and regulatory risks tied to claim collections remain key challenges.
Zacks·3mo ago
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.
Zacks·4mo ago
ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside
ICCC earns "Outperform" rating with record Q1 sales, margin gains and growth potential tied to Re-Tain's FDA progress and new product formats.